The role of interferon in cancer therapy: A current perspective

CA: A Cancer Journal for Clinicians

Volumn 38, Issue 5, 1988, Pages 258-277

  Goldstein, David ^a   Laszlo, John ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; DRUG MECHANISM; HUMAN; HYPOTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

HUMAN; INTERFERON TYPE I; INTERFERONS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0024273530     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.38.5.258     Document Type: Article

References (102)

1. Contributions to the knowledge of sarcoma
2. Virus interference: I: the interferon
3. The interferon system in man: Nature of the interferon molecules and mode of action
4. The gene for the human immune interferon receptor is located on chromosome 6
5. Four different forms of interferon induced 2′5′ oligo(A)synthetase identified by immunoblotting in human cells
6. Biochemical pathways in interferon action
7. Molecular mechanisms of interferon action
8. Induction of tryptophan degradation in vitro and in vivo: a gamma interferon stimulated activity
9. Interferon therapy in cancer: From imaginon to interferon
10. Interferons and oncogenes
11. Heterogeneity of natural killer cells
12. Modulation of immune functions by interferons
13. Interferons, cytostatic and immunomodulatory effects
14. Structure and function of human interferon gamma
15. Phase I study of pharmacological and immunological effects of human lympho‐blastoid interferon given to patients with cancer
16. Effectiveness of alfa n 1 at an ultra low dose in the treatment of hairy cell leukemia
17. Re combinant leukocyte A interferon: An active agent in advanced cutaneous T‐cell lymphomas
18. Interferon β2 living up to its name
19. Bsf‐2 is not just a differentiation factor
20. Alpha‐interferon induces remission in hairy cell leukemia without enhancement of natural killing
21. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia
22. Human leukocyte interferon and intermittent high dose melphalan‐prednisone administration in the treatment of multiple myeloma: A randomized clinical trial from the myeloma group in central Sweden
23. Recombinant interferon alpha‐2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: A prospective randomized trial
24. Treatment of multiple myeloma with recombinant alpha‐interferon
25. Phase II study of rDNA alpha‐2 interferon in patients with multiple myeloma using an escalation induction phase
26. Alpha‐2‐interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: A Phase I‐II trial
27. Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte α interferon
28. Recombinant alpha‐2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome
29. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: Clinical response and prognostic parameters
30. Treatment of acquired immunodeficiency syndrome—related Kaposi's sarcoma with lymphoblastoid interferon
31. Alpha interferon therapy of Kaposi's sarcoma in AIDS
32. A randomized study of low and high doses of leukocyte alpha interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial
33. Interferon‐therapy of renal cancer
34. Phase II study of alpha interferon on renal cell carcinoma
35. High dose lymphoblastoid interferon in advanced renal cell carcinoma
36. A phase II trial of high‐dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma
37. Treatment of renal cell carcinoma with α(human leukocyte) interferon and vinblastine in combination: A phase I‐II trial
38. Comparison of intramuscular and intravenous recombinant α‐2 interferon in melanoma and other cancers
39. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: Results in 96 patients
40. Combination of fibroblast interferon, carboxamide and cimetidine for advanced malignant melanoma
41. Recombinant interferon alfa‐2a in advanced malignant melanoma: A phase I‐II study in combination with DTIC
42. Leukocyte interferon‐induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma
43. Leukocyte‐derived interferon (alpha) in human breast carcinoma: The American Cancer Society Phase II trial
44. Treatment of malignant carcinoid tumors with human leukocyte interferon: Long‐term results
45. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon
46. Cervical intraepithelial neoplasia treated by perilesional injection of interferon
47. Phase I study of recombinant human interferon beta in patients with advanced cancer
48. Phase I study of recombinant β ser 17 interferon in the treatment of cancer
49. Phase I evaluation of a synthetic mutant of β‐interferon
50. Phase I/II trial of human recombinant β‐interferon ser in patients with renal cell carcinoma
51. ser) in patients with colorectal cancer
52. Phase II trial of recombinant beta interferon in advanced colorectal cancer
53. A phase I clinical trial of recombinant DNA gamma interferon
54. Phase I study of iv administered recombinant gamma interferon in cancer patients
55. Recombinant interferon‐γ(immuneron): Results of a phase I trial in patients with cancer
56. Recombinant γ interferon induces hypertrigly‐ceridemia and inhibits post‐heparin lipase activity in cancer patients
57. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma
58. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma
59. Phase II study of recombinant gamma interferon in patients with advanced non‐osseous sarcomas
60. A randomized Phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma
61. Phase II study of recombinant interferon gamma in patients with disseminated malignant melanoma
62. Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon
63. Phase I study of recombinant interferon alpha and recombinant interferon gamma in cancer patients
64. Phase I trial of recombinant interferons beta(ser) and gamma in patients with advanced malignancy
65. Antibody delivery and effector cell activation in a phase II trial of recombinant γ‐interferon and the murine monoclonal antibody C017–1A in advanced colorectal carcinoma
66. Lymphokine‐activated cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin
67. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay
68. Positive interaction between human interferon and cyclophosphamide or Adriamycin in a human tumor model system
69. Interferons, a group of multiple lymphokines
70. Phase I combined modality clinical trial of alpha‐2‐interferon and radiotherapy
71. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine
72. Influence of low dose beta interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy
73. Toxicity of IFN
74. Prospectively randomized toxicity study of high‐dose versus low‐dose treatment strategies for lymphoblastoid interferon
75. Central nervous system toxicity of interferon
76. Resistance to recombinant interferon alfa‐2a in hairy‐cell leukemia associated with neutralizing anti‐interferon antibodies
77. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa‐2a by intramuscular injection
78. Biologicals and biological response modifiers: Fourth modality of cancer treatment
79. Treatment of hairy cell leukemia (HCL) with recombinant α‐interferon
80. Recombinant alpha‐2‐interferon for hairy cell leukemia
81. A Phase II trial of recombinant leukocyte A interferon for advanced hairy cell leukemia
82. Intron A, recombinant alpha‐2 interferon (IFN) for the treatment of hairy cell leukemia
83. Recombinant alpha‐2 interferon in the treatment of hairy cell leukemia
84. Interferon is effective in hairy‐cell leukaemia
85. Prolonged treatment of advanced hairy cell leukemia with recombinant α‐2 interferon
86. Leukocyte interferon‐induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma
87. Interferon treatment for multiple myeloma
88. Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon
89. Recombinant alfa interferon in renal cell carcinoma: A randomized trial of two routes of administration
90. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma
91. Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society Phase II trial
92. Effects of recombinant interferon on tumor growth and immune responses in patients with metastatic melanoma
93. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma
94. Clinical evaluation of recombinant interferon alfa 2A in metastatic melanoma using two different schedules
95. 2‐interferon plus doxorubicin in patients with solid tumors
96. Interferon and doxorubicin in renal cell carcinoma
97. Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer
98. Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J
99. di‐fluoromethylornithine and leukocyte interferon: A phase I study in cancer patients